[{"id":"d7d6598c-31e5-4bc3-b406-5e9ff144fe1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03834740","created_at":"2021-01-18T18:56:01.539Z","updated_at":"2024-07-02T16:35:04.374Z","phase":"Phase 1","brief_title":"A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection","source_id_and_acronym":"NCT03834740","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B","pipe":" | ","alterations":" PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression","tags":["PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CCNE1 • CDK4 • CDKN2B • PIK3R1 • CASP3 • FOXM1 • PIK3C2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • CCND1 expression • PIK3CA mutation + PTEN mutation • PIK3R1 mutation • CCNE1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 02/18/2022","primary_completion_date":" 02/18/2022","study_txt":" Completion: 02/18/2022","study_completion_date":" 02/18/2022","last_update_posted":"2024-05-10"},{"id":"6e3c6084-780b-4258-9265-a9d002f1e26e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02065063","created_at":"2021-01-18T09:30:41.657Z","updated_at":"2024-07-02T16:37:10.376Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors","source_id_and_acronym":"NCT02065063","lead_sponsor":"GlaxoSmithKline","biomarkers":" BRAF • NRAS • FOXM1","pipe":" | ","alterations":" NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • NRAS wild-type","tags":["BRAF • NRAS • FOXM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 04/22/2014","start_date":" 04/22/2014","primary_txt":" Primary completion: 06/23/2016","primary_completion_date":" 06/23/2016","study_txt":" Completion: 06/23/2016","study_completion_date":" 06/23/2016","last_update_posted":"2018-06-01"}]